Model AUC* Sensitivity (%) Specificity (%)
Simple treatment history    
Cross validation      
1 0.829 63.64 84.23
2 0.824 67.51 81.68
3 0.827 65.24 80.43
4 0.784 61.21 79.60
5 0.813 64.08 80.72
Mean 0.815 64.34 81.33
       
Committee average performance with 375 test TCEs 0.870 66.67 90.48
95% CI 0.87-0.97 41-87 87-93
       
Individual treatment history      
Cross validation      
1 0.837 64.86 85.06
2 0.821 61.18 84.42
3 0.834 62.52 86.56
4 0.798 60.43 83.49
5 0.811 61.55 81.26
Mean 0.820 62.11 84.16
       
Committee average performance with 375 test TCEs 0.855 61.11 87.47
95% CI 0.76-0.95 36-83 85-92
Results from common rules-based genotype interpretation systems**
Stanford HIVdb 0.591 47.06 41.26
95% CI 0.49-0.69 [23, 72] [36, 47]
ANRS v2011.05 0.573 23.53 61.03
95% CI 0.45-0.69 [7,50] [56,66]
REGA v8.0.2 0.566 35.29 54.44
95% CI 0.44-0.69 [14, 62] [49, 60]
*AUC=area under the (receiver-operator characteristic) curve. ** Based on 366 TCEs after those containing maraviroc or raltegravir were removed
Table 2: Performance of the models during cross validation and independent testing.
Goto home»